The impact of COVID-19 on formation and evaluation of portfolio performance: A case of Indonesia

This paper examines how to build a portfolio and assess the impact of the COVID-19 on portfolio performance using the Sharpe single index model. The research sample consists of ten high market capitalization stocks representing five price fractions of the population listed stocks on the Indonesia St...

Full description

Saved in:
Bibliographic Details
Published inInvestment management & financial innovations Vol. 18; no. 3; pp. 63 - 73
Main Authors Nurhayati, Immas, Endri, Endri, Suharti, Titing, Shinta Aminda, Renea, Muniroh, Leny
Format Journal Article
LanguageEnglish
Published Sumy Business Perspectives Ltd 2021
LLC "CPC "Business Perspectives
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:This paper examines how to build a portfolio and assess the impact of the COVID-19 on portfolio performance using the Sharpe single index model. The research sample consists of ten high market capitalization stocks representing five price fractions of the population listed stocks on the Indonesia Stock Exchange during the COVID-19 outbreak from March 1 to May 31, 2020. The results show that there are four stocks that are included in the portfolio formation, namely CASA with a proportion of 50%, BNLI with a proportion of 26 %, UNVR with a proportion of 15%, and HMSP with a proportion of 9%. Based on portfolio performance testing using the Sharpe single index model, it is known that the portfolio during the COVID-19 has a negative Sharpe ratio, meaning that portfolio performance is underperforming. The findings provide evidence that COVID-19 has had a negative impact on the stock market so that many investors have suffered losses on their portfolios. The implications of findings are that investors must evaluate portfolio performance and restructure the formation of new portfolios by considering the COVID-19 pandemic outbreak as a systematic risk factor that can determine the expected returns.
ISSN:1810-4967
1812-9358
DOI:10.21511/imfi.18(3).2021.06